Information Provided By: 
Fly News Breaks for March 20, 2017
JAZZ
Mar 20, 2017 | 10:59 EDT
BMO Capital analyst Gary Nachman calls Jazz Pharmaceuticals' positive Phase 3 data for JZP-110 in two obstructive sleep apnea studies an "important milestone." The data appear to demonstrate a "very solid clinical profile for this novel wake-promoting agent" and "significantly" de-risk the program, Nachman tells investors in a research note. He reiterates an Outperform rating on Jazz shares and says the stock remains a top pick.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
